← FDA DRUG APPROVALS

FDA ANDA · ANDA084951

MENEST

Sponsor: MONARCH PHARMS

APPLICATION
ANDA084951
TYPE
ANDA
ORIGINAL APPROVAL
1977-09-28
LATEST ACTION
2024-02-15
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

MENESTDiscontinued
ESTROGENS, ESTERIFIED 0.3MG · TABLET · ORAL

Approval history

2024-02-15Labeling · Supplement 25 · standardAP
2019-04-08Labeling · Supplement 24 · standardAP
2004-12-01Labeling · Supplement 20AP
2001-12-05Manufacturing (CMC) · Supplement 16AP
2001-12-05Manufacturing (CMC) · Supplement 14AP
2001-12-05Labeling · Supplement 17AP
2001-12-05Manufacturing (CMC) · Supplement 15AP
2000-04-28Manufacturing (CMC) · Supplement 13AP
1999-03-22Manufacturing (CMC) · Supplement 12AP
1994-07-18Manufacturing (CMC) · Supplement 11AP
1992-04-13Labeling · Supplement 10AP
1990-05-10Labeling · Supplement 9AP
1982-06-02Manufacturing (CMC) · Supplement 3AP
1977-09-28OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →